Childhood cancers trials in South Korea
64 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleTrial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Where
- Seoul
- People
- 64 worldwide
- Run by
- RayzeBio, Inc.
See details and how to joinNCT06590857 - Phase 2/3Taking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Daegu, Seoul
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - Phase 1/2Taking peopleA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Seoul
- Age
- 1 month to 17 years
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - No phaseTaking peopleImjudo & Imfinzi PMS
- Where
- Busan, Goyang, Seongnam, Seoul, Suwon
- People
- 246
- Run by
- AstraZeneca
See details and how to joinNCT06544629 - Phase 1Taking peopleA Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Seoul
- Age
- 6 months to 17 years
- People
- 18 worldwide
- Run by
- AbbVie
See details and how to joinNCT07306832 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - No phaseNot yet taking people in South KoreaRepotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion
- Where
- Seoul
- Age
- 12 years and over
- People
- 10
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07599007 - Phase 1/2Taking peopleA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Where
- Seoul
- Age
- Up to 25 years
- People
- 75 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00 - Phase 1/2Taking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Gyeonggi-do, Seoul
- Age
- 12 years and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Seoul
- Age
- 12 years to 100 years
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - No phaseTaking peopleDurvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
- Where
- Seoul
- People
- 50
- Run by
- AstraZeneca
See details and how to joinNCT06995833 - No phaseTaking peopleReal-World Treatment Study of Koselugo (Selumetinib)
- Where
- Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju, Yangsan
- Age
- 3 years to 99 years
- People
- 200
- Run by
- AstraZeneca
See details and how to joinNCT06360406 - Phase 2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- Where
- Seoul
- Age
- 12 years and over
- People
- 100 worldwide
- Run by
- AbbVie
See details and how to joinNCT07196644 · EU 2024-518871-74-00 - No phaseTaking peopleLong-term Follow up Local Registry Study of Kymriah in South Korea
- Where
- Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, Ulsan
- Age
- 0 years to 100 years
- People
- 500
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06785818 - Phase 2Taking peopleEvaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
- Age
- 1 year to 22 years
- People
- 90
- Run by
- Ho Joon Im
See details and how to joinNCT05827549 - Phase 2Taking peopleTreatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Seoul, Suwon, Yangsan
- Age
- 1 year to 9 years
- People
- 116
- Run by
- Hee Young Ju
See details and how to joinNCT06099366 - Phase 2Taking peopleTreatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
- Where
- Incheon, Seoul, Suwon, Yangsan
- Age
- 1 year to 19 years
- People
- 370
- Run by
- Jae Wook Lee
See details and how to joinNCT06184009 - Phase 2Taking peopleTreatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
- Age
- 1 year to 19 years
- People
- 74
- Run by
- Hyoung Jin Kang
See details and how to joinNCT06257394 - Phase 2Taking peopleEfficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Pusan, Seoul
- Age
- Up to 2 years
- People
- 40
- Run by
- Yonsei University
See details and how to joinNCT06516679 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Hwasun, Pusan, Seoul, Suwon
- Age
- 8 years and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - Phase 1/2Taking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Seoul
- Age
- 6 months to 17 years
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - Phase 1/2Taking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Cheongju-si, Hwasun-eup, Hwasun-gun, Seoul
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 3Taking peopleONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
- Where
- Bundang-gu, Seongnam-si, Bundang-Gu, Seongnam-Si, Gangnam, Gangnam-Gu, Ilsandong-gu, Goyang-si, Jongno-gu, Seoul
- People
- 510 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT05580562 · EU 2022-502051-56-00 - Phase 1/2Taking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Hwasun, Seoul
- Age
- 12 years and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555 - No phaseNot yet taking people in South KoreaProspective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
- Where
- Seoul
- People
- 600
- Run by
- Asan Medical Center
See details and how to joinNCT07382505